TWI814723B - Kdm4抑制劑 - Google Patents
Kdm4抑制劑 Download PDFInfo
- Publication number
- TWI814723B TWI814723B TW107110863A TW107110863A TWI814723B TW I814723 B TWI814723 B TW I814723B TW 107110863 A TW107110863 A TW 107110863A TW 107110863 A TW107110863 A TW 107110863A TW I814723 B TWI814723 B TW I814723B
- Authority
- TW
- Taiwan
- Prior art keywords
- kdm4
- cells
- cancer
- methyl
- cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762478785P | 2017-03-30 | 2017-03-30 | |
| US62/478,785 | 2017-03-30 | ||
| US201762513875P | 2017-06-01 | 2017-06-01 | |
| US62/513,875 | 2017-06-01 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201840537A TW201840537A (zh) | 2018-11-16 |
| TWI814723B true TWI814723B (zh) | 2023-09-11 |
Family
ID=63678220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW107110863A TWI814723B (zh) | 2017-03-30 | 2018-03-29 | Kdm4抑制劑 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20200039938A1 (https=) |
| EP (1) | EP3600301B1 (https=) |
| JP (1) | JP7442439B2 (https=) |
| ES (1) | ES2991090T3 (https=) |
| TW (1) | TWI814723B (https=) |
| WO (1) | WO2018183370A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3160952T1 (sl) * | 2014-06-25 | 2021-07-30 | Celgene Quanticel Research, Inc. | Zaviralci histon demetilaz |
| EP3600301B1 (en) | 2017-03-30 | 2024-07-03 | Albert-Ludwigs-Universität Freiburg | Kdm4 inhibitors |
| CN113876953B (zh) * | 2020-07-02 | 2022-12-09 | 中国科学院上海营养与健康研究所 | 新型细胞衰老干预靶点及其在化疗抗癌中的靶向应用 |
| JP2024518712A (ja) * | 2021-04-09 | 2024-05-02 | タキオン セラピューティクス，インコーポレーテッド | Ｋｄｍ４阻害剤による癌の処置 |
| WO2023023112A1 (en) * | 2021-08-18 | 2023-02-23 | Celgene Corporation | Process for preparing histone demethylase inhibitors |
| EP4452249A4 (en) * | 2021-12-23 | 2026-03-11 | Tachyon Therapeutics Inc | PHARMACEUTICAL FORMULATIONS COMPRISING 3-({[(4R)-7-{METHYL[4-(PROPAN-2-YL)PHENYL]AMINO}-3,4-DIHYDRO-2H-L-BENZOPYRAN-4-YL]METHYL}AMINO)PYRIDINE-4-CARBOXYLIC ACID |
| KR20250067936A (ko) * | 2022-09-21 | 2025-05-15 | 셀진 코포레이션 | 3-(｛[(4r)-7-｛메틸[4-(프로판-2-일)페닐]아미노｝-3,4-디하이드로-2h-1-벤조피란-4-일]메틸｝아미노)피리딘-4-카르복실산l-라이신 염의 결정형, 히스톤 탈메틸화효소 억제제 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| CN101851173A (zh) | 2001-09-14 | 2010-10-06 | 梅特希尔基因公司 | 组蛋白脱乙酰化酶抑制剂 |
| GB0307643D0 (en) | 2003-04-02 | 2003-05-07 | Cyclacel Ltd | Markers |
| UA89035C2 (ru) | 2003-12-03 | 2009-12-25 | Лео Фарма А/С | Эфиры гидроксамовых кислот и их фармацевтическое применение |
| DE102004039876A1 (de) | 2004-06-23 | 2006-01-26 | Lanxess Deutschland Gmbh | Herstellung von fluorierten 1,3-Benzodioxanen |
| AR059733A1 (es) | 2006-03-07 | 2008-04-23 | Smithkline Beecham Corp | Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion |
| US7898712B2 (en) | 2008-06-27 | 2011-03-01 | Lockheed Martin Corporation | Risley integrated steering module |
| GB201112607D0 (en) | 2011-07-22 | 2011-09-07 | Glaxo Group Ltd | Novel compounds |
| EP2712316A1 (en) * | 2011-02-08 | 2014-04-02 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders |
| CA2834548C (en) | 2011-04-28 | 2021-06-01 | The Broad Institute, Inc. | Inhibitors of histone deacetylase |
| WO2013143597A1 (en) | 2012-03-29 | 2013-10-03 | Glaxo Group Limited | Demethylase enzymes inhibitors |
| WO2014089368A1 (en) | 2012-12-05 | 2014-06-12 | Bio-Rad Laboratories, Inc | Methods for polymerase chain reaction copy number variation assays |
| CA2894399A1 (en) | 2012-12-06 | 2014-06-12 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
| SMT201800070T1 (it) | 2012-12-19 | 2018-03-08 | Celgene Quanticel Res Inc | Inibiorti di istone demetilasi |
| BR112015014968A2 (pt) | 2012-12-21 | 2017-07-11 | Quanticel Pharmaceuticals Inc | inibidores de histona-desmetilase |
| UY35395A (es) | 2013-03-12 | 2014-10-31 | Abbvie Inc | Inhibidores de bromodominios tetracíclicos |
| SG10201804471PA (en) | 2013-10-18 | 2018-07-30 | Celgene Quanticel Research Inc | Bromodomain inhibitors |
| US9890434B2 (en) * | 2014-03-19 | 2018-02-13 | National Tsing Hua University | Method for identifying compound for inhibiting an activity of a histone lysine demethylase |
| CA2943824A1 (en) * | 2014-03-31 | 2015-10-08 | Gilead Sciences, Inc. | Inhibitors of histone demethylases |
| KR102400920B1 (ko) | 2014-05-01 | 2022-05-20 | 셀젠 콴티셀 리서치, 인크. | 리신 특이적 데메틸라제-1의 억제제 |
| SI3160952T1 (sl) | 2014-06-25 | 2021-07-30 | Celgene Quanticel Research, Inc. | Zaviralci histon demetilaz |
| WO2017117154A1 (en) | 2015-12-28 | 2017-07-06 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| EP3600301B1 (en) | 2017-03-30 | 2024-07-03 | Albert-Ludwigs-Universität Freiburg | Kdm4 inhibitors |
| JP6781095B2 (ja) | 2017-03-31 | 2020-11-04 | エア・ウォーター株式会社 | 化合物半導体基板 |
| WO2019083594A1 (en) | 2017-08-21 | 2019-05-02 | The General Hospital Corporation | COMPOSITIONS AND METHODS FOR CLASSIFYING TUMORS WITH INSTABILITY OF MICROSATELLITES |
| UY38349A (es) | 2018-08-30 | 2020-03-31 | Array Biopharma Inc | Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met |
| JP2024518712A (ja) | 2021-04-09 | 2024-05-02 | タキオン セラピューティクス，インコーポレーテッド | Ｋｄｍ４阻害剤による癌の処置 |
| WO2023023112A1 (en) | 2021-08-18 | 2023-02-23 | Celgene Corporation | Process for preparing histone demethylase inhibitors |
-
2018
- 2018-03-27 EP EP18774276.2A patent/EP3600301B1/en active Active
- 2018-03-27 US US16/498,714 patent/US20200039938A1/en not_active Abandoned
- 2018-03-27 JP JP2020503253A patent/JP7442439B2/ja active Active
- 2018-03-27 US US15/936,811 patent/US20180290977A1/en not_active Abandoned
- 2018-03-27 ES ES18774276T patent/ES2991090T3/es active Active
- 2018-03-27 WO PCT/US2018/024624 patent/WO2018183370A2/en not_active Ceased
- 2018-03-29 TW TW107110863A patent/TWI814723B/zh active
-
2022
- 2022-05-20 US US17/749,233 patent/US12516024B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US12516024B2 (en) | 2026-01-06 |
| WO2018183370A3 (en) | 2018-12-20 |
| JP7442439B2 (ja) | 2024-03-04 |
| EP3600301A2 (en) | 2020-02-05 |
| WO2018183370A2 (en) | 2018-10-04 |
| US20240076271A1 (en) | 2024-03-07 |
| JP2020515645A (ja) | 2020-05-28 |
| EP3600301B1 (en) | 2024-07-03 |
| ES2991090T3 (es) | 2024-12-02 |
| US20200039938A1 (en) | 2020-02-06 |
| TW201840537A (zh) | 2018-11-16 |
| US20180290977A1 (en) | 2018-10-11 |
| EP3600301A4 (en) | 2020-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI814723B (zh) | Kdm4抑制劑 | |
| US10537561B2 (en) | CSF-1R inhibitors for treatment of brain tumors | |
| JP2022017495A (ja) | 癌を治療するための併用療法 | |
| CN105582014B (zh) | 用于治疗白血病的组合物和方法 | |
| JP2022050631A (ja) | Ｔｇ０２によるがん治療 | |
| Zhao et al. | CRISPR-Cas9 library screening combined with an exosome-targeted delivery system addresses tumorigenesis/TMZ resistance in the mesenchymal subtype of glioblastoma | |
| US11666580B2 (en) | Mechanism of resistance to bet bromodomain inhibitors | |
| US9573899B2 (en) | USP7 inhibitor compounds and methods of use | |
| JP2025503385A (ja) | メニン－ｍｌｌエピジェネティック複合体を破壊することによる消化管間質腫瘍（ｇｉｓｔ）の治療的標的化 | |
| WO2012079232A1 (zh) | 用于治疗癌症的化合物及其应用 | |
| WO2014082085A1 (en) | Use of itk inhibitors for the treatment of cancer | |
| JP2021519302A (ja) | 微小残存がんを治療する方法 | |
| Zhang et al. | Retracted: long noncoding RNA MT1JP inhibits proliferation, invasion, and migration while promoting apoptosis of glioma cells through the activation of PTEN/Akt signaling pathway | |
| US20220280590A1 (en) | Use of inhibitors of yap and sox2 for the treatment of cancer | |
| TW202412766A (zh) | Ｆａｋ抑制劑及拓撲異構酶抑制劑的藥物組合及用途 | |
| US10213449B2 (en) | Compositions and methods for treating medulloblastoma | |
| JP2020061973A (ja) | 大腸癌患者の選択方法 | |
| US20240398814A1 (en) | Kras inhibitor and hdac inhibitor combination for the treatment of cancer | |
| Tiwary et al. | Novel peptide targeting CXCR4 disrupt tumor-stroma crosstalk to eliminate migrating cancer stem cells | |
| Tiwary et al. | A CXCR4 targeting peptide delivered by silica nanoparticles eliminates migrating cancer stem cells in pancreatic ductal adenocarcinoma | |
| Tinsley | Mutant KRAS promotes CIP2A-mediated suppression of PP2A-B56a to initiate development of pancreatic ductal adenocarcinoma | |
| Class et al. | Patent application title: USE OF INHIBITORS OF YAP AND SOX2 FOR THE TREATMENT OF CANCER Inventors: Chunling Yi (Washington, DC, US) Shigekazu Murakami (Bethesda, MD, US) Assignees: GEORGETOWN UNIVERSITY | |
| Berenguer Roque et al. | Xanthatin nanocrystals exert anti-inflammatory properties against TNFα-primed 2D monolayers and in 3D spheroids of human HT29 colorectal cancer cells | |
| Ramachandran | Repurposing pimavanserin, an antipsychotic drug for pancreatic cancer and medulloblastoma treatment | |
| Lee | The Role of Gfi1 Family Oncogenes in Medulloblastoma |